title: [Current therapeutic indications of thalidomide and lenalidomide].
abstract: Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications. It was thought to be one of the safest sedatives ever produced as it was effective in small doses, was not addictive, and did not have acute side-effects such as motor impairment, but was quickly removed from market after it was linked to cases of severe birth defects. The Food and Drug Administration approved use in the treatment of erythema nodosum leprosum. Further, it was shown its effectiveness in unresponsive dermatological conditions such as actinic prurigo, adult Langerhans cell hystiocytosis, aphthous stomatitis, Behçet syndrome, graft-versus-host disease, cutaneous sarcoidosis, erythema multiforme, Jessner-Kanof lymphocytic infiltration of the skin, Kaposi sarcoma, lichen planus, lupus erythematosus, melanoma, prurigo nodularis, pyoderma gangrenosum and others. In May 2006, it was approved for the treating multiple myeloma. New thalidomide analogues have been developed but lack clinical experience. This paper is a review of the history, pharmacology, mechanism of action, clinical applications and side effects of thalidomide and its analogues.
authors.affiliation: Servicio de Medicina Interna, Hospital Vall d'Hebron, Instituto de Investigación Vall d'Hebron, Universidad Autónoma de Barcelona, Barcelona, España. Electronic address: Jordi@vhebron.net.
authors.forename: Josep
authors.initials: J
authors.lastname: Ordi-Ros
authors.affiliation: Servicio de Clínica Médica, Hospital Provincial del Centenario, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina.
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Cosiglio
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D003095:Collagen Diseases / Q000188:drug therapy; D004700:Endocrine System Diseases / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006086:Graft vs Host Disease / Q000188:drug therapy; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy; D000077269:Lenalidomide; D009369:Neoplasms / Q000188:drug therapy; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D056737:Safety-Based Drug Withdrawals; D012871:Skin Diseases / Q000188:drug therapy; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D019851:Thrombophilia / Q000139:chemically induced; D014657:Vasculitis / Q000188:drug therapy
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide
keywords: Lenalidomida; Lenalidomide; Talidomida; Terapeutica; Thalidomide; Therapeutic